Display options
Cite
Capristo AF, Del Giudice MM, Alfaro C, et al. Corticosteroid-sparing effect of chromoglycate sodium and nedocromil. Mediators Inflamm. 1994;3(7):S25-30doi: 10.1155/S0962935194000712.
Capristo, A. F., Del Giudice, M. M., Alfaro, C., & Maiello, N. (1994). Corticosteroid-sparing effect of chromoglycate sodium and nedocromil. Mediators of inflammation, 3(7), S25-30. https://doi.org/10.1155/S0962935194000712
Capristo, A F, et al. "Corticosteroid-sparing effect of chromoglycate sodium and nedocromil." Mediators of inflammation vol. 3,7 (1994): S25-30. doi: https://doi.org/10.1155/S0962935194000712
Capristo AF, Del Giudice MM, Alfaro C, Maiello N. Corticosteroid-sparing effect of chromoglycate sodium and nedocromil. Mediators Inflamm. 1994;3(7):S25-30. doi: 10.1155/S0962935194000712. PMID: 18475599; PMCID: PMC2365591.
Copy Download .nbib Format: NLM
Share it on

Mediators Inflamm. 1994;3(7):S25-30. doi: 10.1155/S0962935194000712.

Corticosteroid-sparing effect of chromoglycate sodium and nedocromil.

Mediators of inflammation

A F Capristo, M M Del Giudice, C Alfaro, N Maiello

Affiliations

  1. Paediatric Clinic University of Naples via Sant'Andrea delle Dame Naples 4-1-80100 Italy.

PMID: 18475599 PMCID: PMC2365591 DOI: 10.1155/S0962935194000712

Abstract

The most appropiate management for bronchial asthma is the control of airway inflammation. Corticosteroids are the most effective anti-inflammatory drugs available, but they have a number of side effects; most of these are dose-dependent. In children, asthma control should be accomplished with low steroid doses possibly given by inhalation. In a double-bind placebo-controlled crossover study a group of children with mild to moderate asthma received NED 16 mg/day or BDP 400 mug/day. Values for FEV(1), PEF, symptoms use ofbronchodilators overlapped, whereas bronchial hyper-responsiveness assessed by histamine bronchoprovocation challenge was better with BDP than NED. In another case, one boy with high bronchial hyper-reactivity assessed by provocation test with hypertonic solution, experienced a significant improvement only after 2 weeks of therapy with Deflazacort (2 mg/Kg/day) followed by 4 months on combined treatment with NED (16 mg/day) and BDP (300 mu/day). Authors conclude that NED could have a steroidsparing effect over long-term use.

References

  1. J Allergy Clin Immunol. 1992 Nov;90(5):808-15 - PubMed
  2. Postgrad Med J. 1974 Sep;50 suppl 4:53-9 - PubMed
  3. Eur Respir J. 1991 Sep;4(8):992-9 - PubMed
  4. J Allergy Clin Immunol. 1988 Feb;81(2):449-54 - PubMed
  5. Am Rev Respir Dis. 1992 Mar;145(3):669-74 - PubMed
  6. Br Med J. 1976 Aug 21;2(6033):457-8 - PubMed
  7. Clin Allergy. 1984 Nov;14(6):537-40 - PubMed
  8. J Allergy Clin Immunol. 1981 Apr;67(4):317-24 - PubMed
  9. J Allergy Clin Immunol. 1986 Jul;78(1 Pt 1):36-43 - PubMed
  10. Pediatr Pulmonol. 1992 Feb;12(2):84-9 - PubMed
  11. J Allergy Clin Immunol. 1987 May;79(5):734-40 - PubMed
  12. Allergy. 1991 May;46(4):312-5 - PubMed
  13. J Allergy Clin Immunol. 1991 May;87(5):976-83 - PubMed
  14. Lancet. 1990 Jul 21;336(8708):137-40 - PubMed
  15. J Asthma. 1992;29(2):117-20 - PubMed
  16. Respir Med. 1990 Jul;84(4):317-23 - PubMed
  17. Curr Med Res Opin. 1989;11(8):533-42 - PubMed
  18. Thorax. 1989 Aug;44(8):654-9 - PubMed
  19. Respiration. 1992;59(2):97-101 - PubMed
  20. Am Rev Respir Dis. 1993 Mar;147(3):697-704 - PubMed
  21. Thorax. 1988 Dec;43(12):982-6 - PubMed
  22. Eur J Respir Dis Suppl. 1986;147:330-5 - PubMed
  23. Am Rev Respir Dis. 1990 Jan;141(1):21-8 - PubMed
  24. J Allergy Clin Immunol. 1991 Feb;87(2):483-9 - PubMed
  25. J Allergy Clin Immunol. 1991 Nov;88(5):742-8 - PubMed
  26. Eur Respir J. 1993 Nov;6(10):1507-20 - PubMed
  27. Eur J Respir Dis Suppl. 1986;147:336-9 - PubMed
  28. J Allergy Clin Immunol. 1984 Jul;74(1):41-8 - PubMed

Publication Types